We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+8.96%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.6B
AUM Growth
+$1.15B
Cap. Flow
-$3.6B
Cap. Flow %
-4.89%
Top 10 Hldgs %
20.8%
Holding
3,102
New
50
Increased
790
Reduced
2,114
Closed
100

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$269M
2
MSFT icon
Microsoft
MSFT
+$172M
3
AMZN icon
Amazon
AMZN
+$114M
4
DIS icon
Walt Disney
DIS
+$62.4M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$61.8M

Sector Composition

Rank Sector Weight
1 Technology 22.61%
2 Financials 14.26%
3 Healthcare 12.86%
4 Consumer Discretionary 12.27%
5 Industrials 9.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HROW icon
2926
Harrow
HROW
$1.51B
$109K ﹤0.01%
16,129
-590
-4% -$4.83K
BCLI
2927
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$108K ﹤0.01%
1,882
NL icon
2928
NLI Holdings
NL
$317M
$106K ﹤0.01%
14,285
PSEC icon
2929
Prospect Capital
PSEC
$1.17B
$106K ﹤0.01%
13,818
+24
+0.2% +$166
PXLW icon
2930
Pixelworks
PXLW
$41.6M
$106K ﹤0.01%
2,680
+119
+5% +$4.96K
AYTU icon
2931
AYTU BioPharma
AYTU
$25.3M
$105K ﹤0.01%
+692
New +$110K
APTX
2932
DELISTED
Aptinyx Inc. Common Stock
APTX
$105K ﹤0.01%
34,996
+825
+2% +$2.96K
LJPC
2933
DELISTED
La Jolla Pharmaceutical Company
LJPC
$104K ﹤0.01%
24,411
ELOX
2934
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$99K ﹤0.01%
744
-90
-11% -$13.8K
AQST icon
2935
Aquestive Therapeutics
AQST
$494M
$98K ﹤0.01%
18,815
-925
-5% -$4.92K
MLSS icon
2936
Milestone Scientific
MLSS
$42.6M
$97K ﹤0.01%
27,166
-1,940
-7% -$6.65K
LOGC
2937
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$97K ﹤0.01%
13,340
+175
+1% +$1.44K
ASPS icon
2938
Altisource Portfolio Solutions
ASPS
$65.8M
$96K ﹤0.01%
1,301
+2
+0.2% +$167
ASPU
2939
DELISTED
ASPEN GROUP, INC.
ASPU
$96K ﹤0.01%
15,942
+525
+3% +$4.72K
CYCN icon
2940
Cyclerion Therapeutics
CYCN
$16.7M
$95K ﹤0.01%
1,708
+5
+0.3% +$376
XCUR icon
2941
Exicure
XCUR
$8.57M
$95K ﹤0.01%
291
-16
-5% -$5.51K
FNHC
2942
DELISTED
FedNat Holding Company Common Stock
FNHC
$94K ﹤0.01%
20,225
IDN icon
2943
Intellicheck
IDN
$79.6M
$92K ﹤0.01%
10,931
-970
-8% -$11.4K
ULBI icon
2944
Ultralife
ULBI
$106M
$92K ﹤0.01%
11,129
CKPT
2945
DELISTED
Checkpoint Therapeutics
CKPT
$89K ﹤0.01%
2,820
-241
-8% -$8.08K
DYAI icon
2946
Dyadic International
DYAI
$36.4M
$88K ﹤0.01%
16,097
RMTI icon
2947
Rockwell Medical
RMTI
$28.2M
$86K ﹤0.01%
673
-111
-14% -$16.4K
PFSW
2948
DELISTED
PFSweb, Inc.
PFSW
$86K ﹤0.01%
12,741
NEXT icon
2949
NextDecade
NEXT
$1.78B
$84K ﹤0.01%
31,327
+150
+0.5% +$333
PTRS
2950
DELISTED
Partners Bancorp Common Stock
PTRS
$84K ﹤0.01%
11,489

Similar funds

RhumbLine Advisers's Q1 2021 Portfolio in Review

As of Q1 2021, RhumbLine Advisers held 3,102 positions worth $73.6B, up 1.6% from $72.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers withdrew a net $3.6B in Q1 2021, closing 100 positions and reducing 2,114 holdings. Its most notable exit was Tiffany & Co., an estimated $26.8M position sold in full.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.

Against the trend, RhumbLine Advisers opened a new position in NXP Semiconductors worth $42.7M.

  • RhumbLine Advisers's largest Q1 2021 buy was NXP Semiconductors: 211,843 shares worth $42.7M.
  • RhumbLine Advisers added most to International Flavors & Fragrances in Q1 2021, an estimated $27.4M increase.
  • RhumbLine Advisers's biggest Q1 2021 reduction was Apple, cutting an estimated $269M.
  • RhumbLine Advisers fully exited Tiffany & Co. in Q1 2021, selling an estimated $26.8M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $73.6B portfolio in Q1 2021.
  • RhumbLine Advisers opened 50 new positions and closed 100 in Q1 2021.
  • RhumbLine Advisers's portfolio value rose 1.6% quarter-over-quarter to $73.6B.

Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.